235 related articles for article (PubMed ID: 28851403)
1. A rectal cancer feasibility study with an embedded phase III trial design assessing magnetic resonance tumour regression grade (mrTRG) as a novel biomarker to stratify management by good and poor response to chemoradiotherapy (TRIGGER): study protocol for a randomised controlled trial.
Battersby NJ; Dattani M; Rao S; Cunningham D; Tait D; Adams R; Moran BJ; Khakoo S; Tekkis P; Rasheed S; Mirnezami A; Quirke P; West NP; Nagtegaal I; Chong I; Sadanandam A; Valeri N; Thomas K; Frost M; Brown G
Trials; 2017 Aug; 18(1):394. PubMed ID: 28851403
[TBL] [Abstract][Full Text] [Related]
2. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
[TBL] [Abstract][Full Text] [Related]
3. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial.
Bahadoer RR; Dijkstra EA; van Etten B; Marijnen CAM; Putter H; Kranenbarg EM; Roodvoets AGH; Nagtegaal ID; Beets-Tan RGH; Blomqvist LK; Fokstuen T; Ten Tije AJ; Capdevila J; Hendriks MP; Edhemovic I; Cervantes A; Nilsson PJ; Glimelius B; van de Velde CJH; Hospers GAP;
Lancet Oncol; 2021 Jan; 22(1):29-42. PubMed ID: 33301740
[TBL] [Abstract][Full Text] [Related]
4. Relationship Between Baseline Rectal Tumor Length and Magnetic Resonance Tumor Regression Grade Response to Chemoradiotherapy: A Subanalysis of the TRIGGER Feasibility Study.
Hodges N; Battersby N; Rao S; Brown G;
Ann Surg Oncol; 2023 Aug; 30(8):4729-4735. PubMed ID: 35771366
[TBL] [Abstract][Full Text] [Related]
5. PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer.
Sclafani F; Brown G; Cunningham D; Wotherspoon A; Tait D; Peckitt C; Evans J; Yu S; Sena Teixeira Mendes L; Tabernero J; Glimelius B; Cervantes A; Thomas J; Begum R; Oates J; Chau I
Ann Oncol; 2016 Aug; 27(8):1557-65. PubMed ID: 27217542
[TBL] [Abstract][Full Text] [Related]
6. Early MRI predictors of disease-free survival in locally advanced rectal cancer from the GRECCAR 4 trial.
Nougaret S; Castan F; de Forges H; Vargas HA; Gallix B; Gourgou S; Rouanet P;
Br J Surg; 2019 Oct; 106(11):1530-1541. PubMed ID: 31436325
[TBL] [Abstract][Full Text] [Related]
7. ACRNaCT trial protocol: efficacy of adjuvant chemotherapy in patients with clinical T3b/T4, N+ rectal Cancer undergoing Neoadjuvant Chemoradiotherapy: a pathology-oriented, prospective, multicenter, randomized, open-label, parallel group clinical trial.
Li Q; Luo D; Zhu J; Yang L; Liu Q; Ma Y; Liang L; Cai S; Zhang Z; Li X;
BMC Cancer; 2019 Nov; 19(1):1117. PubMed ID: 31729964
[TBL] [Abstract][Full Text] [Related]
8. Comparison between MRI and pathology in the assessment of tumour regression grade in rectal cancer.
Sclafani F; Brown G; Cunningham D; Wotherspoon A; Mendes LST; Balyasnikova S; Evans J; Peckitt C; Begum R; Tait D; Tabernero J; Glimelius B; Roselló S; Thomas J; Oates J; Chau I
Br J Cancer; 2017 Nov; 117(10):1478-1485. PubMed ID: 28934761
[TBL] [Abstract][Full Text] [Related]
9. SPAR - a randomised, placebo-controlled phase II trial of simvastatin in addition to standard chemotherapy and radiation in preoperative treatment for rectal cancer: an AGITG clinical trial.
Jameson MB; Gormly K; Espinoza D; Hague W; Asghari G; Jeffery GM; Price TJ; Karapetis CS; Arendse M; Armstrong J; Childs J; Frizelle FA; Ngan S; Stevenson A; Oostendorp M; Ackland SP
BMC Cancer; 2019 Dec; 19(1):1229. PubMed ID: 31847830
[TBL] [Abstract][Full Text] [Related]
10. Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis.
Renehan AG; Malcomson L; Emsley R; Gollins S; Maw A; Myint AS; Rooney PS; Susnerwala S; Blower A; Saunders MP; Wilson MS; Scott N; O'Dwyer ST
Lancet Oncol; 2016 Feb; 17(2):174-183. PubMed ID: 26705854
[TBL] [Abstract][Full Text] [Related]
11. Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE).
Kim CW; Kang BM; Kim IY; Kim JY; Park SJ; Park WC; Bae KB; Bae BN; Baek SK; Baik SH; Son GM; Lee YS; Lee SH
BMC Cancer; 2018 May; 18(1):538. PubMed ID: 29739356
[TBL] [Abstract][Full Text] [Related]
12. Local excision in mid-to-low rectal cancer patients who revealed clinically total or near-total regression after preoperative chemoradiotherapy; a proposed trial.
Lee JL; Lim SB; Yu CS; Park IJ; Yoon YS; Kim CW; Park SH; Lee JS; Hong YS; Kim SY; Kim JE; Kim JH; Park JH; Kim J; Han M
BMC Cancer; 2019 Apr; 19(1):404. PubMed ID: 31035949
[TBL] [Abstract][Full Text] [Related]
13. Preoperative concurrent chemoradiotherapy MRI characteristics favouring pathologic complete response in patients with rectal cancer: Usefulness of MR T2-stage as an ancillary finding for predicting pathologic complete response.
Lee HJ; Chung WS; An JH; Kim JH
J Med Imaging Radiat Oncol; 2021 Apr; 65(2):166-174. PubMed ID: 33319450
[TBL] [Abstract][Full Text] [Related]
14. Histological grading based on poorly differentiated clusters is predictive of tumour response and clinical outcome in rectal carcinoma treated with neoadjuvant chemoradiotherapy.
Reggiani Bonetti L; Lionti S; Domati F; Pagliani G; Mattioli E; Barresi V
Histopathology; 2017 Sep; 71(3):393-405. PubMed ID: 28425130
[TBL] [Abstract][Full Text] [Related]
15. Rsf-1 expression in rectal cancer: with special emphasis on the independent prognostic value after neoadjuvant chemoradiation.
Lin CY; Tian YF; Wu LC; Chen LT; Lin LC; Hsing CH; Lee SW; Sheu MJ; Lee HH; Wang YH; Shiue YL; Wu WR; Huang HY; Hsu HP; Li CF; Chen SH
J Clin Pathol; 2012 Aug; 65(8):687-92. PubMed ID: 22569540
[TBL] [Abstract][Full Text] [Related]
16. NORAD01-GRECCAR16 multicenter phase III non-inferiority randomized trial comparing preoperative modified FOLFIRINOX without irradiation to radiochemotherapy for resectable locally advanced rectal cancer (intergroup FRENCH-GRECCAR- PRODIGE trial).
Brouquet A; Bachet JB; Huguet F; Karoui M; Artru P; Sabbagh C; Lefèvre JH; Vernerey D; Mariette C; Vicaut E; Benoist S;
BMC Cancer; 2020 May; 20(1):485. PubMed ID: 32471382
[TBL] [Abstract][Full Text] [Related]
17. [Evaluation of progression-free survival for locally advanced rectal cancer by MRI after neoadjuvant chemoradiotherapy and total mesorectal excision].
Zhang JX; Yang Z; Fan P; Zhang JJ; Xin L; Hou LN; Du XS; Yang XT
Zhonghua Zhong Liu Za Zhi; 2018 Feb; 40(2):121-126. PubMed ID: 29502372
[No Abstract] [Full Text] [Related]
18. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
Bosset JF; Calais G; Mineur L; Maingon P; Stojanovic-Rundic S; Bensadoun RJ; Bardet E; Beny A; Ollier JC; Bolla M; Marchal D; Van Laethem JL; Klein V; Giralt J; Clavère P; Glanzmann C; Cellier P; Collette L;
Lancet Oncol; 2014 Feb; 15(2):184-90. PubMed ID: 24440473
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant-intensified treatment for rectal cancer: time to change?
Musio D; De Felice F; Bulzonetti N; Guarnaccia R; Caiazzo R; Bangrazi C; Raffetto N; Tombolini V
World J Gastroenterol; 2013 May; 19(20):3052-61. PubMed ID: 23716984
[TBL] [Abstract][Full Text] [Related]
20. The effects of neoadjuvant chemoradiotherapy and an in-hospital exercise training programme on physical fitness and quality of life in locally advanced rectal cancer patients (The EMPOWER Trial): study protocol for a randomised controlled trial.
Loughney L; West MA; Kemp GJ; Rossiter HB; Burke SM; Cox T; Barben CP; Mythen MG; Calverley P; Palmer DH; Grocott MP; Jack S
Trials; 2016 Jan; 17():24. PubMed ID: 26762365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]